Data indicates it will retain robust antiviral activity against current variants of concern, company says
Pfizer announced Tuesday that its coronavirus candidate pill, PAXLOVID, appears to work against the new omicron variant.
The US pharmaceutical company said recent data “indicates that PAXLOVID will retain robust antiviral activity against current variants of concern.”
“Emerging variants of concern, like omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorised or approved, this potential treatment could be a critical tool to help quell the pandemic,” it added.
The company said the data is based on final results from an analysis of 2,246 adults enrolled in its phases 2-3 trials of PAXLOVID.
It added that PAXLOVID reduces the risk of hospitalization or death by 88%.